Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease

Digestive Diseases and Sciences

Volumn 60, Issue 7, 2015, Pages 2119-2129

  Veerappan, Sundaram G ^a,b   Healy, Martin ^c   Walsh, Bernard J ^c   O’Morain, Colm A ^b   Daly, Jacqueline S ^a   Ryan, Barbara M ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Adalimumab; Bone metabolism; Crohn s disease; Osteoporosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; MERCAPTOPURINE; MESALAZINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; CELL DIFFERENTIATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAINTENANCE THERAPY; MALE; NUTRITIONAL STATUS; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; CASE CONTROL STUDY; CELL LINE; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BONE DENSITY; CASE-CONTROL STUDIES; CELL LINE; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOBLASTS; YOUNG ADULT;

EID: 84930821612     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3606-z     Document Type: Article

References (30)

1. Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralization and growth retardation in inflammatory bowel disease. Invest Radiol. 1976;11:541–549.
2. Bjarnasson I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228–233.
3. Pollak RD, Karmeli F, Eilakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483–1490.
4. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251–255.
5. Silvennoinen JA, Karttunen TJ, Niemelia SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71–76.
6. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1895–1902.
7. Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest. 1997;99:1699–1703.
8. Oelzner P, Franke S, Muller A, Hein G, Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford). 1999;38:841–847.
9. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913–917.
10. Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297–1301.
11. Lanfranchi GA, Tragnone A. Serum and faecal tumour necrosis factor-alpha as marker of intestinal inflammation. Lancet. 1992;339:1053.
12. Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology. 1996;111:1263–1271.
13. Hyams JS, Wyzga N, Kreutzer DL, Justrinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr. 1997;24:289–295.
14. Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol. 2001;187:294–303.
15. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn’s disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res. 2002;17:695–702.
16. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2004;20:607–614.
17. Ryan BM, Russel MGVM, Schurgers L, et al. Effect of antitumour necrosis factor-α therapy on bone turnover in patients with active Crohn’s disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851–857.
18. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn’s disease. J Clin Gastroenterol. 2006;40:55–63.
19. Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z. Infliximab therapy improves the bone metabolism in fistulizing Crohn’s disease. Dig Dis. 2006;24:201–206.
20. Miheller P, Muzes G, Rácz K, et al. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis. 2007;13:1379–1384.
21. Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn’s disease. Ann N Y Acad Sci. 2006;1068:543–556.
22. Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn’s disease patients. Can J Gastroenterol. 2007;21:637–642.
23. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol. 2005;100:2031–2035.
24. Krieckaert CL, Nurmohammed MT, Wolbink G, Lems WF. Changes in bone mineral density during long-term treatment with Adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;52:547–553.
25. Harris SA, Enger RJ, Riggs BL, Spelsberg TC. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res. 1995;10:178–186.
26. Lancaster MV, Fields RD. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents. US Patent No. 5,501,959; 1996.
27. Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn’s disease: a population-based case control study. Inflamm Bowel Dis. 2005;11:325–330.
28. Ghosh S, Cowen S, Hannan W, Ferguson A. Low bone mineral density in Crohn’s disease but not in ulcerative colitis at diagnosis. Gastroenterology. 1994;107:1031–1039.
29. Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol. 1997;159:6276–6282.
30. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology. 2000;119:639–646.